Over the past decade, treatment in a variety of cancers, particularly breast cancer, chronic myelogenous leukemia, and non-small cell lung cancer, has switched from intermittent intravenous therapy to self-administered targeted oral anticancer medications (OAMs). There are more than 50 of…
AllazoHealth continues to lead in advancing the use of artificial intelligence in healthcare. Building on our success in medication adherence, we have expanded our implementation of AI to include therapy initiation. Barriers to therapy initiation Therapy initiation is a critical…
This year's election could have a major effect on adherence rates. Here are some possible changes in healthcare policy that could be enacted under Trump or Biden, and the impact on adherence. Revocation of the ACA In November, the Supreme…
Polypharmacy, the simultaneous use of multiple drugs, is becoming more common as the population ages. More than 30% of older adults in the United States take five or more drugs, typically for multiple chronic conditions. How polypharmacy contributes to non-adherence…
We live in exciting times for adherence, and the pharma industry is playing a critical role, according to Mark Degatano, a pharmaceutical industry analytics expert who is on the advisory board of AllazoHealth. Degatano’s expertise comes from 24 years with…
Are you responsible for improving your plan’s quality ratings? Learn how to improve your performance on Star and other quality measures. Download our deck and get specific advice for payers on: The influence of population mix on performance Which patients…
Payers, pharmacies and pharmaceutical companies are starting to join providers in recognizing that social determinants of health (SDOH) have a major impact on patient adherence and clinical outcomes. Healthcare organizations now face the challenge of finding ways to analyze and…
With medication non-adherence costing the industry more than $600 billion a year, many pharmaceutical companies are creating medication adherence programs, often in conjunction with pharmacists and payers. According to Andrea Kasprzyk, Director of Sales at AllazoHealth, "The objective of an…
Besides being a financial issue for pharmaceutical companies, unfilled prescriptions can lead to poorer health outcomes, drive up overall cost of care, and can have an impact on provider performance under value-based payment models. Pharmaceutical companies often use copay assistance…
Partnering with Blue Cross Blue Shield of North Carolina on a randomized control trial, AllazoHealth demonstrated a 5.5 times uplift in adherence compared with traditional programs. In addition, the study showed our artificial intelligence (AI) engine delivered over 97% accuracy…